Company
Helix BioPharma Corp.
TSE:HBP
Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer-based on its proprietary technologies - DOS47. It is a naturally occurring enzyme that converts urea into ammonia and generates an alkaline media at the site of action. This effectively combats the acidic tumor microenvironment that is known to suppresses the immune system. Helix’s product development initiatives include its lead candidate L-DOS47 which is currently in clinical studies for lung and pancreatic cancer.
39 stories · page 1 of 2
Helix BioPharma closes private placement financing for net proceeds of C$4,629,019.86
“We would like to thank all investors for their strong support and confidence in Helix. We look forward to continued efforts toward this exciting program” said Artur Gabor, CEO of Helix
Helix BioPharma advances clinical development of lead candidate L-DOS47, but manages to decrease R&D expenses in 2022 fiscal year
For the 2022 fiscal year ended July 31, 2022, the Toronto-based biopharma company reported R&D expenses of $4,544,000, a sharp decrease from $5,880,000 in the 2021 fiscal year
Helix BioPharma appoints Dr. Frank Gary Renshaw as Chief Medical Officer
"Dr. Renshaw will bring to Helix BioPharma his several decades of development experience in oncology-hematology, Molecular/Immuno-Oncology drug research. We look forward to his leadership in helping shape the future of our work at Helix," s
Helix BioPharma names Dr Gabrielle Siegers as head of research and development
Dr Siegers has been tasked to help Helix make significant breakthroughs in the field of immune oncology
Helix BioPharma announces scientific collaboration with University Hospital Tuebingen in Germany
“We expect this collaboration to result in new and additional insight into the therapeutic response of L-DOS47 in several not yet explored preclinical cancer models expressing CEACAM6," said company CEO Artur Gabor
Helix BioPharma closes private placement financing for net proceeds of $2,002,000 with shareholder Jerzy Wilczewski
As a result of the closing of the private placement, Wilczewski now owns or exercises control or direction over 31,167,153 common shares, representing approximately 19.85% of the issued and outstanding common shares of the company on a non-
Helix BioPharma appoints Artur Gabor as its new CEO; adds three new board members
The clinical-stage biopharmaceutical company said Jerzy Leszczyński, Christopher Maciejewski, and Jacek Antas will join its board effective immediately
Helix BioPharma announces sudden passing of interim CEO Slawomir Majewski
"Slawek was an exceptional executive - but more importantly - he was an exceptional human being,” said Artur Gabor on behalf of the Board
Helix BioPharma closes a private placement financing for gross proceeds of $1,001,000 from the issuance of 3,850,000 common shares
The company said it intends to use the net proceeds of the private placement for working capital and advancing its L-DOS47 drug development program
Helix BioPharma spends C$1.24M on R&D in its fiscal first quarter
The company has developed an immune-oncology drug platform (DOS47) to treat cancer, which is designed to turn the tumor's environment to alkaline from acid, which, in turn, corrects an impaired immune system
Helix BioPharma increased crucial spending on research and development for the 2021 fiscal year
The company spent around $5.88 million on R&D costs for the 2021 fiscal year ended July 31, 2021, as the biopharma continued to develop drugs to treat cancer
Helix BioPharma advancing efforts to combat killer cancers with unique immuno-oncology therapies
The firm is developing an immune-oncology drug platform (DOS47) for the treatment of cancer
Helix BioPharma appoints paediatric surgeon Dr. Krzysztof Saczek to its board of directors
Currently, he is the head of the Paediatric Surgery Department at the Regina General Hospital in Regina, Saskatchewan
Helix BioPharma plans management shakeup in September
Herman Chao has announced plans to resign as CEO and Chief Scientific Officer
Archive
NA Proactive news snapshot: Spotlite360 Technologies, BioHarvest Sciences, Kainantu Resources, KushCo Holdings, Nextleaf Solutions UPDATE …
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Helix BioPharma spends C$1.9M on R&D in its fiscal third quarter
The company has developed an immune-oncology drug platform (DOS47) to treat cancer
Helix BioPharma closes first tranche of previously announced private placement with Lind Global Macro Fund for gross proceeds of C$3.5M
Under the first tranche, the company has issued a convertible security with a two-year term and a face value of $4,112,500 and an aggregate of 1,957,056 common share purchase warrants